UBS maintains Eli Lilly at Buy, raises price target to $1625 from $1425

What happened

UBS kept its Buy rating on Eli Lilly and raised its price target to $1625 from $1425, an increase of 14.0%. The revised target implies 14.6% upside from the Oct. 30 closing price of $1417.54.

Confirmed

Global impact / market context

A higher price target signals that UBS sees more potential value in Eli Lilly shares, which may support investor interest. However, the target is an analyst estimate, not a promised return, and it does not change the company’s sales, costs, or cash available by itself.

Analyst inference

The five most recent analyst notes cited, published over 30 days, set targets from $1500 to $1650, placing UBS’s revised $1625 target near the upper end. This spread shows analysts differ in their estimates, rather than establishing a certain future share price.

Confirmed

What to watch

1. Compare future analyst targets with Eli Lilly’s reported sales and earnings; results materially below expectations could weaken the business case behind higher share-price estimates. Analyst inference
2. Watch for further analyst rating or target changes, since the supplied notes show a range of $1500 to $1650 among five recent opinions. Analyst inference
3. Track whether Eli Lilly’s upcoming company disclosures provide evidence that its operating results support the higher valuation UBS has assigned. Analyst inference

Evidence

• Original source link unavailable